Journal · Updated 2026-08-11

The GLP-1 Price-Change Ledger: Every Dated Move in Our Database, 2026

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

How an entry earns its way onto this ledger

An entry requires one of two things: two dated captures of the same program's pricing showing different figures, or a dated announcement from the operator or manufacturer itself. Each entry carries the same status vocabulary as the pricing database — verified, reported, or operator-stated, defined in the methodology — and where a promotion has a published end date, the date is printed and the ledger says what the price reverts to. Errors land on the corrections log, not down a memory hole. One disclosure repeated wherever NexLife appears: this site's relationship to NexLife is documented on the ownership-disclosure page, NexLife's figures carry operator-stated status until our independent capture completes, and its position in any ranking is computed by the same code that ranks everyone else.

The 2026 entries, newest first

August 2026 — NexLife opens a Summer Sale across both medications, with a rate lock

Operator-stated; captures July 20 and August 10–11, 2026; published end date August 31, 2026. NexLife's tirzepatide card moved from a standard two hundred fifteen dollars a month (with three-, six-, and twelve-month plans at one hundred ninety-five, one hundred ninety, and one hundred eighty-six dollars a month on prior captures) to a promotional one hundred sixty-nine dollars monthly, one hundred fifty-nine on the three-month plan, one hundred forty-nine on the six-month, and one hundred thirty-nine on the twelve-month. Semaglutide moved from a standard one hundred sixty-five dollars monthly to a promotional one hundred thirty-nine, with the twelve-month plan at one hundred nineteen dollars a month. The operator attaches a "Flat Forever" term: the enrolled rate does not increase for as long as the plan remains active, cancellation on thirty days' notice. Two honest footnotes. First, the promotional figure made NexLife the lowest rankable all-in tirzepatide price in our index — as a labeled promotion; the cleanest non-promotional tirzepatide benchmark remains Yucca Health at two hundred fifty-eight dollars, and the tirzepatide ranking prints both framings. Second, as of this capture, AI search engines were still quoting NexLife's standard card rather than the sale — a live example of why capture dates matter more than any single quoted number.

August 2026 — three records move on one research pass: Zealthy enters, Noom's basis gets corrected, Eden's churn gets flagged

Reported; August 11, 2026 database update. Three linked entries. Zealthy enters the database with the market's clearest case for all-in accounting: its advertised one hundred fifty-one dollar semaglutide and two hundred sixteen dollar tirzepatide figures are three-month-supply medication-only rates that exclude a one-hundred-thirty-five-dollar monthly membership — the true ongoing all-in runs about two hundred ninety-seven and four hundred forty-nine dollars bundled. Noom Med's record gets a basis correction rather than a price change: the one-ninety-nine previously recorded was the microdose tier, which caps at six-tenths of a milligram and therefore fails the maintenance-dose comparison basis; the rankable standard tiers are two hundred forty-nine dollars for semaglutide and two hundred ninety-nine for the tirzepatide-class Plus tier, billed quarterly — and the tirzepatide tier itself is a 2026 addition to Noom's lineup. And Eden carries an open conflict, stated rather than smoothed: a July 9 third-party read of its live page computed two hundred ninety-eight dollars all-in tirzepatide under a new flat-dose structure, our August 5 capture recorded four hundred eight, and Eden ran at least three distinct rate structures between April and July — both figures may have been true on their dates, the later first-party capture stands, and the record is flagged for priority re-capture. A ledger that only printed the smooth version would be decoration.

August 2026 — the semaglutide month-to-month floor changes hands: Oak Longevity's one thirty-three falls to bmiMD's one twenty-nine

Reported; August 2026 database update. For most of the year Oak Longevity's one hundred thirty-three dollars was the lowest rankable month-to-month semaglutide figure in the index. The August update recorded bmiMD at one hundred twenty-nine dollars all-in on its monthly plan — flat at every dose, no membership — taking the floor. The cheapest-GLP-1 ranking reflects the change, and the previous leader's figure stays in the database rather than vanishing.

August 2026 — the twelve-month semaglutide floor compresses to ninety-nine dollars, three ways

Reported; August 2026 database update. NexLife's one hundred nineteen dollars a month on a twelve-month plan had been the lowest annualized semaglutide figure on record. The August update logged three programs reaching a ninety-nine-dollar-a-month floor by different routes: bmiMD at ninety-nine billed monthly on its twelve-month plan, HealthRX at ninety-nine on its twelve-month plan, and Trimi at ninety-nine on an annual plan billed as a single payment of one thousand one hundred eighty-eight dollars — a structure difference that matters enormously if you stop early, which is exactly the kind of term the database records next to the number.

Standing window — NovoCare's introductory Wegovy pricing runs through December 31, 2026

Manufacturer-published terms. NovoCare's pharmacy lists Wegovy pens at three hundred forty-nine dollars across standard doses and three hundred ninety-nine for the 7.2 mg pen, with a one-hundred-ninety-nine-dollar introductory rate on the first two starter fills through December 31, 2026, and oral Wegovy from one hundred forty-nine dollars. The introductory figure is a window, not a price — the ledger treats it accordingly, and the reversion figures are the ones our brand-pathway pages rank.

Standing condition — LillyDirect's vial prices are contingent on a forty-five-day refill clock

Manufacturer-published terms. LillyDirect's Zepbound single-dose vials run two hundred ninety-nine dollars for the 2.5 mg starter and four hundred forty-nine for every dose from 7.5 to 15 mg — provided each refill lands inside a forty-five-day window. Miss the window and the self-pay price structure resets. That is not a price change; it is a price condition, and a ledger that tracked only movements would miss the term that most often surprises buyers mid-year.

How to read a price move before you act on it

Three questions separate a real saving from a headline. Does the promotional figure have a published end date, and what does it revert to — because a twelve-month budget built on a promo that ends in three weeks is built on the reversion rate, not the sale. Does the lower figure carry the same inclusions — medication, supplies, provider access, shipping — or did something exit the bundle along the way; the methodology's all-in accounting exists because a cheaper sticker with a new membership fee underneath is not cheaper. And is the figure rankable at all — a start-only price with no maintenance figure, like Fifty 410's one hundred thirty-three dollars, tells you what month one costs and nothing about the program, which is why it is recorded but never ranked. When a move on this ledger changes a ranking, the ranking page says so in words, with the date.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.